These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 10853980)

  • 1. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
    Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
    AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
    Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
    Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
    Bower M; Fox P; Fife K; Gill J; Nelson M; Gazzard B
    AIDS; 1999 Oct; 13(15):2105-11. PubMed ID: 10546864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
    Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
    AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor.
    Murdaca G; Campelli A; Setti M; Indiveri F; Puppo F
    AIDS; 2002 Jan; 16(2):304-5. PubMed ID: 11807324
    [No Abstract]   [Full Text] [Related]  

  • 9. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
    Martinez V; Caumes E; Gambotti L; Ittah H; Morini JP; Deleuze J; Gorin I; Katlama C; Bricaire F; Dupin N
    Br J Cancer; 2006 Apr; 94(7):1000-6. PubMed ID: 16570046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy.
    Núñez M; Saballs P; Valencia ME; Santos J; Ferrer E; Santos I; Berrocal A; Galindo MJ; Podzamczer D; Gonzlez-Lahoz J;
    HIV Clin Trials; 2001; 2(5):429-37. PubMed ID: 11673818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.
    Dupin N; Rubin De Cervens V; Gorin I; Calvez V; Pessis E; Grandadam M; Rabian C; Viard JP; Huraux JM; Escande JP
    Br J Dermatol; 1999 May; 140(5):875-81. PubMed ID: 10354025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.
    Nasti G; Talamini R; Antinori A; Martellotta F; Jacchetti G; Chiodo F; Ballardini G; Stoppini L; Di Perri G; Mena M; Tavio M; Vaccher E; D'Arminio Monforte A; Tirelli U;
    J Clin Oncol; 2003 Aug; 21(15):2876-82. PubMed ID: 12885804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.
    Lupia R; Wabuyia PB; Otiato P; Fang CT; Tsai FJ
    J Microbiol Immunol Infect; 2017 Dec; 50(6):781-788. PubMed ID: 26712092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
    Uldrick TS; Wyvill KM; Kumar P; O'Mahony D; Bernstein W; Aleman K; Polizzotto MN; Steinberg SM; Pittaluga S; Marshall V; Whitby D; Little RF; Yarchoan R
    J Clin Oncol; 2012 May; 30(13):1476-83. PubMed ID: 22430271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
    Gill J; Bourboulia D; Wilkinson J; Hayes P; Cope A; Marcelin AG; Calvez V; Gotch F; Boshoff C; Gazzard B
    J Acquir Immune Defic Syndr; 2002 Dec; 31(4):384-90. PubMed ID: 12447008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
    Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
    Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome.
    Cattelan AM; Calabro ML; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    Eur J Cancer; 1999 Dec; 35(13):1809-15. PubMed ID: 10673996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Kaposi sarcoma in HIV patients: Response to antiretroviral treatment and chemotherapy].
    Lasso M; Pérez J; Noriega L; Malebrán A; Espinoza S
    Rev Med Chil; 2003 May; 131(5):483-90. PubMed ID: 12879808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.